We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Thrombolysis in Myocardial Infarction (TIMI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00000505
Recruitment Status : Completed
First Posted : October 28, 1999
Last Update Posted : March 16, 2016
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI)

Brief Summary:
In TIMI I, to assess the relative thrombolytic activity and side effects of intravenous recombinant tissue-type plasminogen activator (rt-PA) versus intravenous streptokinase in patients with acute myocardial infarction. In TIMI II, to assess whether intravenous rt-PA given in the early hours of acute myocardial infarction should be followed by percutaneous transluminal coronary angioplasty (PTCA).

Condition or disease Intervention/treatment Phase
Cardiovascular Diseases Coronary Disease Heart Diseases Myocardial Infarction Myocardial Ischemia Drug: tissue plasminogen activator Procedure: angioplasty, transluminal, percutaneous coronary Phase 3

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Primary Purpose: Treatment
Study Start Date : April 1983
Actual Study Completion Date : December 1990

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Attack
Drug Information available for: Plasminogen

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Men and women under age 76. Patients had acute myocardial infarction.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000505

Sponsors and Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Layout table for investigator information
OverallOfficial: Joseph Babb Bridgeport Hospital
OverallOfficial: Jeffery Borer Weill Medical College of Cornell University
OverallOfficial: Bernard Chaitman St. Louis University Medical Center
OverallOfficial: James Chesebro Mayo Foundation
OverallOfficial: Richard Davison Northwestern University
OverallOfficial: Harold Dodge University of Washington
OverallOfficial: Frederick Feit NYU Langone Health
OverallOfficial: Charles Francis Yale University
OverallOfficial: Joel Gore University of Massachusetts, Worcester
OverallOfficial: Michael Herman New York Medical College
OverallOfficial: Morrison Hodges University of Minnesota
OverallOfficial: Harvey Kemp St. Luke's-Roosevelt Institute for Health Sciences
OverallOfficial: Genell Knatterud Maryland Medical Research Institute
OverallOfficial: Costas Lambrew MaineHealth
OverallOfficial: Philip Ludbrook Washington University School of Medicine
OverallOfficial: Kenneth Mann University of Vermont
OverallOfficial: John Markis Beth Israel Hospital
OverallOfficial: John Morrison North Shore University Hospital
OverallOfficial: Hiltrud Mueller Montefiore Medical Center
OverallOfficial: Eric Powers Columbia University
OverallOfficial: Robert Roberts Baylor College of Medicine
OverallOfficial: Williams Rogers University of Alabama at Birmingham
OverallOfficial: Allan Ross George Washington University
OverallOfficial: Thomas Ryan University Hospital Inc.
OverallOfficial: Marc Schweiger Baystate Medical Center
OverallOfficial: Gerald Timmis William Beaumont Hospitals
OverallOfficial: James Willerson University of Texas
OverallOfficial: David Williams Rhode Island Hospital
OverallOfficial: Barry Zaret Yale University
Bovill E: Dose Response Relationship of rt-PA Infusion to Induction of Systemic Fibrin(ogen)olysis in the Thrombolysis in Myocardial Infarction (TIMI) Trial. Blood, 70(Suppl 1) 367a, 1987.

Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00000505    
Other Study ID Numbers: 24
R01HL042311 ( U.S. NIH Grant/Contract )
First Posted: October 28, 1999    Key Record Dates
Last Update Posted: March 16, 2016
Last Verified: July 2000
Additional relevant MeSH terms:
Layout table for MeSH terms
Cardiovascular Diseases
Myocardial Infarction
Heart Diseases
Coronary Disease
Myocardial Ischemia
Pathologic Processes
Vascular Diseases
Tissue Plasminogen Activator
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action